DOCSLIB.ORG

Recommendations to Assure the Quality, Safety and Efficacy of Enterovirus 71 Vaccines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recommendations to Assure the Quality, Safety and Efficacy of Enterovirus 71 Vaccines 1 2 3 WHO/EV71/DRAFT/042020 4 ENGLISH ONLY 5 Recommendations to assure the quality, safety and 6 efficacy of Enterovirus 71 vaccines (inactivated) 7 Proposed new recommendations 8 (Draft-version public consultation) 9 10 NOTE: 11 This document has been prepared for the purpose of inviting comments and suggestions on the 12 proposals contained therein, which will then be considered by the Expert Committee on Biological 13 Standardization (ECBS). Publication of this early draft is to provide information about the proposed 14 WHO Recommendations to assure the quality, safety and efficacy of Enterovirus 71 vaccines 15 (inactivated) to a broad audience and to improve transparency of the consultation process. 16 These Recommendations were developed based on the outcomes and consensus of the WHO working 17 group meeting convened in 2018 with participants from national regulatory authorities, national control 18 laboratories, vaccine manufacturers and academia researchers. 19 The text in its present form does not necessarily represent an agreed formulation of the Expert 20 Committee. Written comments proposing modifications to this text MUST be received 21 by 28 May 2020 in the Comment Form available separately and should be addressed to the World 22 Health Organization, 1211 Geneva 27, Switzerland, attention: Department of Health Products Policy 23 and Standards. Comments may also be submitted electronically to the Responsible Officer: 24 Dr Dianliang Lei at email: [email protected]. 25 The outcome of the deliberations of the Expert Committee will be published in the WHO Technical 26 Report Series. The final agreed formulation of the document will be edited to be in conformity with 27 the "WHO style guide, second edition" (KMS/WHP/13.1). 28 29 © World Health Organization 2020 30 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World 31 Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 32 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – 33 whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address 34 (fax: +41 22 791 4806; email: [email protected]). 35 1 1 The designations employed and the presentation of the material in this publication do not imply the 2 expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status 3 of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or 4 boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full 5 agreement. 6 7 The mention of specific companies or of certain manufacturers’ products does not imply that they are 8 endorsed or recommended by the World Health Organization in preference to others of a similar nature that 9 are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by 10 initial capital letters. 11 12 All reasonable precautions have been taken by the World Health Organization to verify the information 13 contained in this publication. However, the published material is being distributed without warranty of any 14 kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the 15 reader. In no event shall the World Health Organization be liable for damages arising from its use. 16 17 The named authors [or editors as appropriate] alone are responsible for the views expressed in this 18 publication. 19 20 2 1 Contents 2 Introduction ............................................................................................................................... 5 3 Scope .......................................................................................................................................... 6 4 Terminology ............................................................................................................................... 6 5 General considerations .............................................................................................................. 8 6 International reference materials ............................................................................................ 10 7 Part A. Manufacturing recommendations ............................................................................. 11 8 A.1 Definitions ................................................................................................................. 12 9 A.2 General manufacturing recommendations ............................................................... 12 10 A.3 Control of source materials ....................................................................................... 12 11 A.4 Control of vaccine production ................................................................................... 16 12 A.5 Filling and containers ................................................................................................ 24 13 A.6 Control tests on the final lot ..................................................................................... 24 14 A.7 Records ...................................................................................................................... 26 15 A.8 Retained samples ...................................................................................................... 27 16 A.9 Labelling .................................................................................................................... 27 17 A.10 Distribution and shipping .......................................................................................... 27 18 A.11 Stability, storage and expiry date.............................................................................. 27 19 Part B Nonclinical Evaluation of EV71 vaccines ....................................................................... 28 20 B.1 Product characterization and process development ..................................................... 29 21 B.2 Primary pharmacodynamics studies .............................................................................. 29 22 B.3 Nonclinical safety studies ............................................................................................... 30 23 Part C. Clinical evaluation of inactivated EV71 vaccines ......................................................... 30 24 C.1 Introduction............................................................................................................... 30 25 C.2 Assays ........................................................................................................................ 31 26 C.3 Immunogenicity ........................................................................................................ 32 27 C.4 Efficacy ...................................................................................................................... 33 28 C.5 Safety ......................................................................................................................... 36 29 Part D. Recommendations for NRAs ........................................................................................ 37 30 D.1 General recommendations ....................................................................................... 37 31 D.2 Official release and certification ............................................................................... 37 32 Authors and acknowledgements ............................................................................................. 38 33 References ............................................................................................................................... 39 3 1 Appendix 1 Model Summary protocol for the manufacturing and control of Enterovirus 71 2 vaccines (inactivated) .............................................................................................................. 45 3 Appendix 2 Model NRA Lot Release Certificate for Enterovirus 71 vaccines (inactivated) .... 48 4 5 4 1 Introduction 2 3 Enterovirus (EV)71 was first isolated from the faeces of a female suffering from encephalitis 4 in 1969 in California (1) although a retrospective study in The Netherlands suggests that it 5 could have emerged as early as 1963 (2), consistent with reports of possible epidemics due to 6 EV71 in the late twentieth century across the world (3). EV71 has since been associated with 7 a range of diseases, including Hand Foot and Mouth Disease (HFMD) throughout the world 8 and with epidemics in Asia, Europe and America. The virus causes a range of effects from 9 asymptomatic infection and mild HFMD, to neurological disease with severe central nerve 10 system (CNS) complications and cardiopulmonary failure. In severe cases, mortality rates can 11 be high, especially in children of 5 years age and younger. EV71 is considered to be the most 12 severe neurotoxic enterovirus. Indeed, severe EV71 disease has become a major public health 13 problem in China. In 2011, the WHO Western Pacific Regional Office issued a “Guide to 14 clinical Management and Public Health Response to Hand, Foot and Mouth Disease(HFMD)” 15 (4) to support the treatment, prevention and control of HFMD. 16 Several vaccines against EV71 virus are under development and three inactivated EV71 17 vaccines have already been licensed in China (5-10). The WHO Expert Committee on 18 Biological Standardization (ECBS), at its 67th
Load more

Recommended publications
  • RNA-Dependent RNA Polymerase Speed and Fidelity Are Not the Only Determinants of the Mechanism Or Efficiency of Recombination
    G C A T T A C G G C A T genes Article RNA-Dependent RNA Polymerase Speed and Fidelity are not the Only Determinants of the Mechanism or Efficiency of Recombination Hyejeong Kim y, Victor D. Ellis III, Andrew Woodman, Yan Zhao, Jamie J. Arnold y and , Craig E. Cameron y * Department of Biochemistry and Molecular Biology, The Pennsylvania State University, 201 Althouse Laboratory, University Park, PA 16802, USA; [email protected] (H.K.); [email protected] (V.D.E.); [email protected] (A.W.); [email protected] (Y.Z.); [email protected] (J.J.A.) * Correspondence: [email protected]; Tel.: +1-919-966-9699 Present address: Department of Microbiology and Immunology, School of Medicine, University of North y Carolina at Chapel Hill, 125 Mason Farm Rd., Chapel Hill, NC 27599-7290, USA. Received: 15 October 2019; Accepted: 21 November 2019; Published: 25 November 2019 Abstract: Using the RNA-dependent RNA polymerase (RdRp) from poliovirus (PV) as our model system, we have shown that Lys-359 in motif-D functions as a general acid in the mechanism of nucleotidyl transfer. A K359H (KH) RdRp derivative is slow and faithful relative to wild-type enzyme. In the context of the KH virus, RdRp-coding sequence evolves, selecting for the following substitutions: I331F (IF, motif-C) and P356S (PS, motif-D). We have evaluated IF-KH, PS-KH, and IF-PS-KH viruses and enzymes. The speed and fidelity of each double mutant are equivalent. Each exhibits a unique recombination phenotype, with IF-KH being competent for copy-choice recombination and PS-KH being competent for forced-copy-choice recombination.
    [Show full text]
  • Rapid Risk Assessment – Enterovirus Detections Associated with Severe Neurological Symptoms in Children and Adults in European Countries, 8 August 2016
    RAPID RISK ASSESSMENT Enterovirus detections associated with severe neurological symptoms in children and adults in European countries 8 August 2016 6 Main conclusions and options for response09 August 2016 Since April 2016, Denmark, France, the Netherlands, Spain, Sweden and United Kingdom (Wales) have reported severe enterovirus infections associated with a variety of different strains. Compared with previous years, the Netherlands and Germany also reported increased detection of enterovirus-D68 and other enteroviruses. In addition, Ireland reported an increasing number in enterovirus-associated viral meningitis cases. The timing of the current epidemics closely follows the usual increase in summer, but reports suggest that seasonal enterovirus (EV) activity in the EU/EEA Member States started earlier than in previous years. Some Member States also report an increased frequency of severe disease associated with EV infection. While it is difficult to interpret these observations in the absence of robust historical data, Member States should consider raising awareness of the importance of including EV infection in the differential diagnosis of neurological and severe respiratory illness in order to identify cases and initiate appropriate precautions, as well as to provide more robust epidemiological information. Reporting of enterovirus clusters and outbreaks through the Early Warning and Response System (EWRS) in EU/EEA countries is encouraged. The full molecular and biological characterisation of the isolates from the current outbreaks will possibly enhance the understanding of the pattern of enterovirus epidemiology in Europe, including trends in subgenotypes associated with more severe clinical disease and molecular epidemiological links to strains between countries and from outside Europe. Increased numbers of EV-A71 and EV-D68 detections reinforce the need for vigilance for enterovirus infections, especially cases that present with more severe clinical syndromes.
    [Show full text]
  • Sentinel Surveillance for Enterovirus 71, Taiwan, 1998
    Dispatches Sentinel Surveillance for Enterovirus 71, Taiwan, 1998 Trong-Neng Wu,* Su-Fen Tsai,* Shu-Fang Li,* Tsuey-Fong Lee,* Tzu-Mei Huang,* Mei-Li Wang,* Kwo-Hsiung Hsu, and Chen-Yang Shen *Disease Surveillance and Quarantine Service, Ministry of Health, Taiwan, Republic of China; Bureau of Communicable Disease Control, Ministry of Health, Taiwan, Republic of China; and Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Republic of China Outbreaks of enterovirus 71 have been reported around the world since 1969. The most recent outbreak occurred in Taiwan during April-July 1998. This hand, foot, and mouth disease epidemic was detected by a sentinel surveillance system in April at the beginning of the outbreak, and the public was alerted. Enterovirus type 71 (EV71), one of the physicians weekly to actively collect disease etiologic agents of epidemic hand, foot, and information. On the basis of information mouth disease (HFMD), has been associated collected, disease incidence trends are predicted, with febrile rash illness, aseptic meningitis, and, if necessary, the public is warned during the encephalitis, and a syndrome of acute flaccid earliest stage of disease outbreaks. Mumps, paralysis similar to that caused by poliovirus varicella, diarrhea, and upper-tract respiratory (1,2). EV71 was identified in 1969 in the United infection are among the diseases subject to States, when it was isolated from the feces of an routine surveillance. For convenience, we have infant with encephalitis in California. By 1998, established two channels of data collection: many EV71 outbreaks had been reported around telephone interviews and report cards mailed by the world.
    [Show full text]
  • Review Antivirals Against Enteroviruses: a Critical Review from a Public-Health Perspective
    Antiviral Therapy 2015; 20:121–130 (doi: 10.3851/IMP2939) Review Antivirals against enteroviruses: a critical review from a public-health perspective Kimberley SM Benschop1*, Harrie GAM van der Avoort1, Erwin Duizer1, Marion PG Koopmans1,2 1Centre for Infectious Diseases Research, Diagnostics and Screening, National Institute for Public Health and the Environment, Bilthoven, the Netherlands 2Department of Viroscience, Erasmus Medical Centre, Rotterdam, the Netherlands *Corresponding author e-mail: [email protected] The enteroviruses (EVs) of the Picornaviridae family are potential emergence of drug-resistant strains and their the most common viral pathogens known. Most EV infec- impact on EV transmission and endemic circulation. We tions are mild and self-limiting but manifestations can include non-picornavirus antivirals that inhibit EV rep- be severe in children and immunodeficient individuals. lication, for example, ribavirin, a treatment for infection Antiviral development is actively pursued to benefit these with HCV, and amantadine, a treatment for influenza A. high-risk patients and, given the alarming problem of They may have spurred resistance emergence in HCV or antimicrobial drug resistance, antiviral drug resistance influenza A patients who are unknowingly coinfected is a public-health concern. Picornavirus antivirals can be with EV. The public-health challenge is always to find a used off-label or as part of outbreak control measures. balance between individual benefit and the long-term They may be used in the final stages of poliovirus eradi- health of the larger population. cation and to mitigate EV-A71 outbreaks. We review the Introduction Enteroviruses (EVs) are among the most common of the PV eradication process and as part of outbreak circulating viruses known.
    [Show full text]
  • Neutralizing Antibodies Can Initiate Genome Release from Human Enterovirus 71
    Neutralizing antibodies can initiate genome release from human enterovirus 71 Pavel Plevkaa,1, Pei-Yin Limb, Rushika Pereraa,2, Jane Cardosab,c, Ampa Suksatua, Richard J. Kuhna, and Michael G. Rossmanna,3 aDepartment of Biological Sciences, Purdue University, West Lafayette, IN 47907; bSentinext Therapeutics, 10050 Penang, Malaysia; and cMAB Explorations, 10050 Penang, Malaysia Edited by Wah Chiu, Baylor College of Medicine, Houston, TX, and approved January 6, 2014 (received for review November 7, 2013) Antibodies were prepared by immunizing mice with empty, imma- Here we present an analysis of the interactions of the mono- ture particles of human enterovirus 71 (EV71), a picornavirus that clonal antibodies E18 and E19 with EV71. By using cryo-EM, we causes severe neurological disease in young children. The capsid show that binding of E18 to EV71 causes the virus to change its structure of these empty particles is different from that of the conformation to the A state and to eject much of its genome. mature virus and is similar to “A” particles encountered when This was further verified by fluorescence activation when SYBR picornaviruses recognize a potential host cell before genome release. Green dyes interact with RNA. In contrast, although mAb E19 The monoclonal antibody E18, generated by this immunization, does neutralize the virus, it has a quite different footprint on the induced a conformational change when incubated at temperatures virus surface and does not cause ejection of the genome. between 4 °C and 37 °C with mature virus, transforming infectious virions into A particles. The resultant loss of genome that was Results and Discussion observed by cryo-EM and a fluorescent SYBR Green dye assay The E18 and E19 antibodies were prepared by immunizing mice inactivated the virus, establishing the mechanism by which the with empty, immature EV71 particles containing VP0 (18).
    [Show full text]
  • Update on Acute Flaccid Myelitis: Recognition, Reporting, Aetiology and Outcomes Duriel Hardy, Sarah Hopkins
    Review Arch Dis Child: first published as 10.1136/archdischild-2019-316817 on 10 February 2020. Downloaded from Update on acute flaccid myelitis: recognition, reporting, aetiology and outcomes Duriel Hardy, Sarah Hopkins Division of Neurology, Children’s ABStract What is already known? Hospital of Philadelphia, Acute flaccid myelitis, defined by acute flaccid limb Philadelphia, Pennsylvania, USA weakness in the setting of grey matter lesions of Acute flaccid myelitis (AFM) presents with the spinal cord, became increasingly recognised in ► Correspondence to sudden paralysis and grey matter abnormality 2014 following outbreaks in Colorado and California, Dr Sarah Hopkins, Neurology, of the spinal cord, related to enteroviruses. Children’s Hospital of temporally associated with an outbreak of enterovirus Philadelphia, Philadelphia, PA Patients have residual disability, and optimal D68 respiratory disease. Since then, there have been management is unclear. 19104, USA; biennial increases in late summer/early fall. A viral hopkinss1@ email. chop. edu infectious aetiology, most likely enteroviral, is strongly Received 8 October 2019 suspected, but a definitive connection has yet to be Revised 8 January 2020 established. Patients typically present with asymmetric What this study adds? Accepted 17 January 2020 weakness, maximal proximally, in the setting of a febrile Published Online First illness. MRI demonstrates T2/FLAIR abnormalities in the 10 February 2020 ► Concise review of current knowledge, including Seguridad Social - BINASSS. Protected by copyright. central grey matter of the spinal cord, and cerebrospinal defining clinical characteristics, need for close fluid typically shows a lymphocytic pleocytosis with monitoring in the acute period, outcomes and variable elevation in protein. The weakness may be questions for further study.
    [Show full text]
  • SIRT1 Inhibits EV71 Genome Replication and RNA Translation By
    © 2016. Published by The Company of Biologists Ltd | Journal of Cell Science (2016) 129, 4534-4547 doi:10.1242/jcs.193698 RESEARCH ARTICLE SIRT1 inhibits EV71 genome replication and RNA translation by interfering with the viral polymerase and 5′UTR RNA Yang Han, Lvyin Wang, Jin Cui, Yu Song, Zhen Luo, Junbo Chen, Ying Xiong, Qi Zhang, Fang Liu, Wenzhe Ho, Yingle Liu*, Kailang Wu* and Jianguo Wu* ABSTRACT Among the mature proteins, EV71 3Dpol protein (3Dpol) acts as a Enterovirus 71 (EV71) possesses a single-stranded positive RNA viral RNA-dependent RNA polymerase (RdRp) and plays a major genome that contains a single open reading frame (ORF) flanked by a role in viral genome synthesis (Richards et al., 2006; Rueckert, ′ 5′ untranslated region (5′UTR) and a polyadenylated 3′UTR. Here, 1996). The EV71 5 UTR RNA contains a cloverleaf structure we demonstrated that EV71 activates the production of silent mating involved in viral RNA transcription and an internal ribosome entry type information regulation 2 homolog 1 (SIRT1), a histone site (IRES) that mediates translation initiation (Rohll et al., 1994). deacetylase (HDAC). EV71 further stimulates SIRT1 sumoylation The cloverleaf structure (stem-loop I) is essential for negative-strand and deacetylase activity, and enhances SIRT1 translocation from the synthesis, which requires a membrane-associated replication nucleus to the cytoplasm. More interestingly, activated SIRT1 complex of viral RNA template along with viral and cellular subsequently binds with the EV71 3Dpol protein (a viral RNA- proteins (Barton et al., 2001; Lyons et al., 2001). The IRES structure – dependent RNA polymerase, RdRp) to repress the acetylation and (stem-loops II VI) is required for viral RNA translation initiation RdRp activity of 3Dpol, resulting in the attenuation of viral genome through a cap-independent mechanism (Thompson and Sarnow, replication.
    [Show full text]
  • Enterovirus A71 Infection, Thailand, 2017
    RESEARCH LETTERS 8. Krief I, Goldblatt JG, Paz A, Potasman I. Late vaccination have been reported annually to the Thailand Ministry of against yellow fever of travelers visiting endemic countries. Public Health (3); CV-A6 and CV-A16 are the main caus- Travel Med Infect Dis. 2006;4:94–8. http://dx.doi.org/10.1016/ j.tmaid.2005.02.001 ative agents. Most reports were based on clinical symp- 9. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of toms; laboratory-based confirmations are rare. Conse- immunity after yellow fever vaccination: systematic review quently, the incidence increased awareness and the need on the need for a booster every 10 years. Am J Trop Med Hyg. for diagnostic-based epidemiologic surveillance. As of 2013;89:434–44. 10.4269/ajtmh.13-0264 http://dx.doi.org/10.4269/ ajtmh.13-0264 September 25, 2017, a total of 59,071 cases of 10. Collaborative group for studies on yellow fever vaccines. HFMD have been reported (4). We determined the preva- Duration of post-vaccination immunity against yellow fever lence and viral etiology of enterovirus infections among in adults. Vaccine. 2014;39:4977–84. PubMed https://doi.org/ patients with clinical HFMD and herpangina in Thailand 10.1016/j.vaccine.2014.07.021 during 2017. Address for correspondence: Fujie Zhang and Hanhui Ye, Beijing Ditan The study was approved by the Chulalongkorn Univer- Hospital, Beijing 100015, China; email: [email protected], and sity Faculty of Medicine Institutional Review Board (insti- [email protected] tutional review board no. 002/60). We tested clinical speci- mens from 482 children requiring hospital care for HFMD (n = 435) and herpangina (n = 47) that were submitted to King Chulalongkorn Memorial Hospital (Bangkok, Thai- land) during January 1–October 30, 2017, from 12 provinces with reported HFMD outbreaks (online Technical Appendix Figure 1, https://wwwnc.cdc.gov/EID/article/24/7/17-1923- Techapp1.pdf).
    [Show full text]
  • Severe Acute Flaccid Myelitis Associated
    Severe Acute Flaccid Myelitis Associated With Enterovirus in Children: Two Phenotypes for Two Evolution Profiles? Melodie Aubart, Cyril Gitiaux, Charles Joris Roux, Raphael Levy, Isabelle Schuffenecker, Audrey Mirand, Nathalie Bach, Florence Moulin, Jean Bergounioux, Marianne Leruez-Ville, et al. To cite this version: Melodie Aubart, Cyril Gitiaux, Charles Joris Roux, Raphael Levy, Isabelle Schuffenecker, et al.. Severe Acute Flaccid Myelitis Associated With Enterovirus in Children: Two Phenotypes for Two Evolution Profiles?. Frontiers in Neurology, Frontiers, 2020, 11, pp.343. 10.3389/fneur.2020.00343. hal-02998679 HAL Id: hal-02998679 https://hal.archives-ouvertes.fr/hal-02998679 Submitted on 4 Jun 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License ORIGINAL RESEARCH published: 28 April 2020 doi: 10.3389/fneur.2020.00343 Severe Acute Flaccid Myelitis Associated With Enterovirus in Children: Two Phenotypes for Two Evolution Profiles? Melodie Aubart 1,2*, Cyril Gitiaux 3,4,
    [Show full text]
  • Rheum Emodin Inhibits Enterovirus 71 Viral Replication and Affects the Host Cell Cycle Environment
    Acta Pharmacologica Sinica (2017) 38: 392–401 © 2017 CPS and SIMM All rights reserved 1671-4083/17 www.nature.com/aps Original Article Rheum emodin inhibits enterovirus 71 viral replication and affects the host cell cycle environment Ting ZHONG1, 2, #, Li-ying ZHANG3, #, Zeng-yan WANG4, Yue WANG5, Feng-mei SONG6, Ya-hong ZHANG7, Jing-hua YU1, * 1Institute of Virology and AIDS Research, The First Hospital of Jilin University, Jilin University, Changchun 130000, China; 2Medicinal Chemistry, College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130000, China; 3Department of Biotechnology, College of Animal Science and Veterinary Medicine, Jilin University, Changchun 130000, China; 4Department of Internal Medicine, The First Hospital of Jilin University, Jilin University, Changchun 130000, China; 5Chemistry of Traditional Chinese Medicine, College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130000, China; 6Department of Experimental Pharmacology and Toxicology, School of Pharmacy, Jilin University, Changchun 130000, China; 7Key Laboratory of Natural Medicines and Immunotechnology of Henan Province, Henan University, Kaifeng 475004, China Abstract Human enterovirus 71 (EV71) is the primary causative agent of recent large-scale outbreaks of hand, foot, and mouth disease (HFMD) in Asia. Currently, there are no drugs available for the prevention and treatment of HFMD. In this study, we compared the anti-EV71 activities of three natural compounds, rheum emodin, artemisinin and astragaloside extracted from Chinese herbs Chinese rhubarb, Artemisia carvifolia and Astragalus, respectively, which have been traditionally used for the treatment and prevention of epidemic diseases. Human lung fibroblast cell line MRC5 was mock-infected or infected with EV71, and treated with drugs. The cytotoxicity of the drugs was detected with MTT assay.
    [Show full text]
  • Recent Advances of Enterovirus 71 3Cpro Targeting Inhibitors Rominah Onintsoa Diarimalala, Meichun Hu, Yanhong Wei and Kanghong Hu*
    Diarimalala et al. Virol J (2020) 17:173 https://doi.org/10.1186/s12985-020-01430-x REVIEW Open Access Recent advances of enterovirus 71 3Cpro targeting Inhibitors Rominah Onintsoa Diarimalala, Meichun Hu, Yanhong Wei and Kanghong Hu* Abstract With CA16, enterovirus-71 is the causative agent of hand foot and mouth disease (HFMD) which occurs mostly in children under 5 years-old and responsible of several outbreaks since a decade. Most of the time, HFMD is a mild disease but can progress to severe complications such as meningitis, brain stem encephalitis, acute faccid paralysis (AFP) and even death; EV71 has been identifed in all severe cases. Therefore, it is actually one of the most public health issues that threatens children’s life. 3Cpro is a protease which plays important functions in EV71 infection. To date, a lot of 3Cpro inhibitors have been tested but none of them has been approved yet. Therefore, a drug screening is still an utmost importance in order to treat and/or prevent EV71 infections. This work highlights the EV71 life cycle, 3Cpro functions and 3Cpro inhibitors recently screened. It permits to well understand all mechanisms about 3Cpro and consequently allow further development of drugs targeting 3Cpro . Thus, this review is helpful for screening of more new 3Cpro inhibitors or for designing analogues of well known 3Cpro inhibitors in order to improve its antiviral activity. Keywords: Enterovirus 71, Enterovirus 71 life cycle, 3Cpro functions, 3Cpro inhibitors, EV71 drugs screening Background the Asia-Pacifc region. Indeed, China has experienced Enterovirus 71, belongs to human enterovirus A spe- the latest and largest outbreaks with more than 1.7 mil- cies, Picornaviridae family, was discovered in a patient lion cases, 27.000 patients with severe neurological com- with central nervous system (CNS), in California, 1969 plications and 905 deaths, in 2010 [5]; while a cyclical [1].
    [Show full text]
  • 8. Enterovirus 71 Encephalitis
    8. Enterovirus 71 Encephalitis LUAN-YIN CHANG, SHIN-RU SHIH, LI-MIN HUANG, AND TZOU-YIEN LIN 8.1. Virology Enterovirus 71 (EV71) was first described in 1974 after it was isolated from patients in California (Schmidt et al., 1974) and has been associated with sporadic cases or outbreaks of a wide spectrum of diseases, including hand, foot, and mouth disease (HFMD), herpangina, aseptic meningitis, encephalitis, cerebellar ataxia, poliomyelitis-like syn- drome, and even fatal disease. Since the poliovirus has been eradicated, EV71 has become one of the most important enteroviruses known to cause fatalities and sequelae in children. Therefore, understanding its virology, epidemiology, clinical manifestations, treatment management, diagnosis, and prevention is important. 8.1.1. Virological Classification of Enterovirus 71 Enterovirus 71 is an enterovirus. Enteroviruses belong to Picornaviridae, a family of single-stranded, positive-sense RNA viruses. They can be classified into four groups: enteroviruses (e.g., poliovirus), rhinoviruses (e.g., human rhinovirus), cardioviruses (e.g., Mengo virus), and aphthovirus (e.g., foot-and-mouth virus). The rhinovirus and enterovirus genera are most closely related; the cardioviruses fall halfway between the two closely related ones and the foot-and-mouth virus, FMDV. Serologic studies, using neutralization tests with antisera against enteroviruses, have identified more than 67 human enterovirus serotypes: poliovirus serotypes 1–3, 23 coxsackie A virus serotypes, 6 coxsackie B virus serotypes, 31 echovirus serotypes, and the numbered enterovirus serotypes (enteroviruses 68–71). 295 296 L-Y. Chang et al. 8.1.2. General Characteristics of Enterovirus Most enteroviruses replicate in primate cells. The specific receptor on the surface of the host cell can be used to identify the host range and tis- sue tropism.
    [Show full text]